Medical device company Enlighten Mobility was awarded $150,000 by the Ohio Third Frontier Technology Validation and Start-up Fund to develop the GMat Neuromotor Screening licensed through Nationwide Children’s Hospital

SOUTH BEND, In., February 15, 2021 – Enlighten Mobility, a medical device company focused on early intervention solutions to advance development and recovery from loss of mobility, was awarded a grant of $150,000 by the Ohio Third Frontier Technology Validation and Start-up Fund (TVSF) to develop and commercialize the GMat Neuromotor Screening tool, the first automated non-invasive neuromotor screening for newborns licensed through an exclusive agreement with Columbus, Oh.-based Nationwide Children’s Hospital.

“Enlighten Mobility is honored to receive the Ohio Third Frontier TVSF grant to advance the clinical research and prototyping necessary to bring the GMat into the marketplace,” said Marissa Koscielski, founder of Enlighten Mobility. “The TVSF grant brings us closer to making automated neuromotor screening accessible to all newborns, creating an improved care pathway with early intervention that never before existed.”

The GMat Neuromotor Screening serves as an objective indicator for further evaluation by using artificial intelligence to detect patterns of variability in newborns that the human eye and brain are unable to process. Designed by a team of Nationwide Children’s Researchers, the GMat accelerates the path to earlier timing and targeting of diagnosis to mitigate loss of vital development opportunities for all children.

According to the Ohio Third Frontier Commission, TVSF provides grants to Ohio institutions of higher education and other nonprofit research institutions. The funding is to demonstrate that a technology is commercially viable through activities such as testing and prototyping, helping companies either raise funds or get licensed technology to the marketplace faster.

Koscielski said studies utilizing the GMat on newborns are currently underway with the Early Detection and Intervention network of the top U.S. neonatal intensive care units as Enlighten Mobility continues product development with Nationwide Children’s Hospital.

About Enlighten Mobility
Enlighten Mobility is a medical device company dedicated to empowering individuals with early intervention solutions to advance development and recovery from loss of mobility due to illness, injury, amputation and stroke. The company leads with clinical research, working alongside patients, caregivers and clinicians to drive innovation for diagnostic devices and rehabilitation technologies that optimize mobility care pathways. Enlighten Mobility holds an exclusive license agreement with Nationwide Children’s Hospital for the first automated non-invasive neuromotor screening, the GMat, currently in studies with the Early Detection and Intervention network of top U.S. neonatal intensive care units. Studies for the company’s patented independent walking device for lower limb amputees, the Enlight Gait Trainer, continue with The Ohio State University Wexner Medical Center. The GMat and Enlight Gait Trainer lead a robust product pipeline that includes neuromodulation integration for stroke and neurological recovery, diagnostic and therapeutic motion analysis, biofeedback augmented reality and at-home endurance training to support telehealth. South Bend, In.-based Enlighten Mobility was founded in 2017 by Marissa Koscielski after she experienced firsthand the lack of effective solutions for her own recovery from temporary unilateral immobility and set out to challenge the status quo of mobility care, which remains the company’s mission today. For more information, visit EnlightenMobility.com.

Enlighten Mobility Communications Contact:
Cathy DeRonne
media@enlightenmobility.com